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Abstract
Background:  The use of microarray technology to assess gene expression levels is now
widespread in biology. The validation of microarray results using independent mRNA quantitation
techniques remains a desirable element of any microarray experiment. To facilitate the comparison
of microarray expression data between laboratories it is essential that validation methodologies be
critically examined. We have assessed the correlation between expression scores obtained for 48
human genes using oligonucleotide microarrays and the expression levels for the same genes
measured by quantitative real-time RT-PCR (qRT-PCR).
Results:  Correlations with qRT-PCR data were obtained using microarray data that were
processed using robust multi-array analysis (RMA) and the MAS 5.0 algorithm. Our results indicate
that when identical transcripts are targeted by the two methods, correlations between qRT-PCR
and microarray data are generally strong (r = 0.89). However, we observed poor correlations
between qRT-PCR and RMA or MAS 5.0 normalized microarray data for 13% or 16% of genes,
respectively.
Conclusion: These results highlight the complementarity of oligonucleotide microarray and qRT-
PCR technologies for validation of gene expression measurements, while emphasizing the
continuing requirement for caution in interpreting gene expression data.
Background
The use of microarray technology to assess gene expres-
sion levels is now widespread in biology and, particularly
in the clinical setting, the applicability of the methodol-
ogy is likely to broaden as the technology evolves, data
analysis procedures improve, and costs decline [1-3]. Two
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distinct microarray platforms, cDNA and oligonucleotide,
are currently in general use [4]. While the relative merits
of the two systems continue to be discussed [5], the vali-
dation of microarray results using independent mRNA
quantitation techniques, including Northern blotting,
ribonuclease protection, in situ hybridization, or quantita-
tive real-time reverse transcription-polymerase chain reac-
tion (qRT-PCR) remains a critical element of any
microarray experiment [6,7]. Despite this, there have been
few systematic validation studies of cDNA, or more
noticeably, oligonucleotide microarray data using these
independent approaches. For researchers to be confident
with the interpretation of microarray results and for the
establishment of consistent validation procedures in the
microarray community for the purpose of data compari-
son, it is important that this issue be addressed.
We have undertaken an extensive series of experiments
examining gene expression profiles in pediatric cancer
specimens and normal tissues using oligonucleotide
microarrays. For these studies, we used HG-U133A Gene-
Chips (Affymetrix) which contain 22,283 probe sets rep-
resenting approximately 14,500 human genes. To
determine the preferred methodology for the analysis of
our microarray data we compared the correlation between
microarray expression scores obtained using two different
data normalization procedures – Affymetrix MAS 5.0 [8],
and robust multi-array analysis (RMA)[9] – with the
expression levels obtained from follow-up verification
experiments using qRT-PCR [10-12].
We found that the correlation between qRT-PCR and
microarray expression data is generally strong. While our
results highlight the complementarity of oligonucleotide
microarray and qRT-PCR technologies for validation of
gene expression measurements, the poor correlations that
we observed for 13–16% of genes emphasizes the impor-
tance and continuing requirement for caution in inter-
preting gene expression data.
Results
We have assessed the degree of correlation between micro-
array expression scores obtained for 48 genes using HG-
U133A GeneChips with expression levels measured for
the same genes using qRT-PCR. The genes that we assessed
were identified as part of a larger study underway in the
laboratory examining differential gene expression in pedi-
atric leukemias and brain tumor specimens. The 48 genes
were targeted for validation either on the basis of their dif-
ferential expression between our subsets of interest (e.g.
brain tumour vs normal brain specimens, leukemia spec-
imens vs normal CD34+ stem cells) as determined by
microarray analysis, or because they mapped to chromo-
somal regions of interest. In those cases where there were
multiple microarray probe sets for particular genes, only
data from those that showed evidence of differential
expression were chosen for validation. For genes that were
selected from chromosomal regions of interest and not
necessarily on the basis of differential expression, correla-
tions were carried out using data from the probe set
deemed most specific for the gene of interest by the
Affymetrix software (e.g. microarray probe sets designated
-at are considered more specific than -s-at and -x-at probe
sets).
In total, 889 specimen/gene combinations were assayed
by qRT-PCR and microarray in this study. Overall, statisti-
cally significant correlations (p < 0.05) were observed
between qRT-PCR and RMA normalized data for 33/48
(69%) genes, and between qRT-PCR and MAS 5.0 normal-
ized data for 32/48 (67%) genes (Tables 1 and 2, genes in
bold). Typical data for a gene with a good correlation is
presented in Figure 1. The correlation between the qRT-
PCR data and microarray data normalized using either of
the two methods was not significant (p > 0.05) for 14/48
(29%) genes (Tables 1 and 2, genes non-bold). Two
genes, FLJ20003 and RB, showed significant correlations
by RMA but not by MAS 5.0 analysis, while one gene,
GCLC, had a significant correlation by MAS 5.0 but not by
RMA.
By careful analysis of the relevant databases (see Methods)
we identified a subset of 31 genes for which the microar-
ray probe-sets were deemed to recognize the exact same
transcript or subset of transcripts as the qRT-PCR probes
(Table 1). When we assessed the levels of correlation for
this group of 31 transcript-concordant genes a higher pro-
portion of significantly correlating scores was observed;
84% (26/31) for MAS 5.0 normalized data and 87% (27/
31) for RMA normalized data (Table 1, genes in bold). In
addition, the average correlations between the MAS 5.0 or
RMA data and the qRT-PCR data for this subset of genes
were very similar (0.71 and 0.72, respectively). In con-
trast, for the remaining 17 genes for which the Affymetrix
microarray probe-sets may not recognize the same subset
of transcript(s) recognized by qRT-PCR probes, significant
correlations were observed for only 41% (7/17) genes by
either MAS 5.0 and RMA (Table 2). All genes with poor
correlations were tested on the same numbers of samples
as those genes that did correlate, and there was no rela-
tionship between sample type and whether or not correla-
tion was significant. Separate genes were targeted for each
sample type. Using a two sample t-test, the average corre-
lations between RMA-qRT-PCR scores and MAS-qRT-PCR
scores for the transcript concordant genes in Table 1 were
significantly higher than the average of the equivalent cor-
relations for the non-concordant genes in Table 2 (RMA-
qRT-PCR Table 1 vs 2, p = 0.0005; MAS-qRT-PCR Table 1
vs 2, p = 0.0003).BMC Genomics 2005, 6:59 http://www.biomedcentral.com/1471-2164/6/59
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Determining fold-changes in gene expression levels
between subsets of interest is often a major aim of micro-
array studies. To address this issue, we analyzed fold-
change in average gene expression levels between our sub-
sets of interest (e. g. tumor vs normal) by both qRT-PCR
and RMA or MAS 5.0 microarray scores for the same
genes. Only the 31 transcript-concordant genes were con-
sidered in this analysis (Table 1). From a total of 587 spec-
imen/gene combinations we found a significant and
strong correlation in mean fold-change using both RMA (r
= 0.89, p < 0.05) and MAS 5.0 (r = 0.92, p < 0.05) (Figure
2a, b). Interestingly, we noticed a trend towards poorer
correlation for genes that exhibited fold-change differ-
ences of <1.5 between subsets of interest based on micro-
array expression scores compared to those with fold-
change differences of >1.5 (data not shown). The slopes of
the two regression lines in Fig. 2 are significantly greater
than one [RMA vs qRT-PCR = 1.49 (95%CI = 1.20, 1.77);
MAS vs qRT-PCR = 1.23 (95% CI = 1.03, 1.42)].
Discussion
Microarray expression analysis has revolutionized many
facets of biology and will continue to be applied widely.
However, significant questions remain with regard to the
generation, analysis, and in particular, interpretation of
microarray data. Although the validation of microarray
expression results obtained for specific genes using inde-
pendent techniques is still considered a desirable
Table 1: A comparison of average qRT-PCR, RMA, and MAS 5.0 scores and the corresponding correlation values for the 31 transcript-
concordant genes assayed in this study for which the Affymetrix microarray probesets (Affy IDs) were deemed likely to recognize 
identical transcripts to qRT-PCR probes. Genes are ranked from lowest to highest average log2 RMA scores. Genes with significant 
correlations (p < 0.05) obtained by either normalization procedure are highlighted in bold. The number of specimens tested for each 
gene is included (n). Expression levels are shown as log2>.
GENE EXPRESSION CORRELATION




LCE 204256_at 22 4.79 7.01 0.27 0.81 0.70
ALDH1A1 212224_at 22 4.93 6.66 -2.93 0.89 0.88
CFLAR 211317_s_at 13 5.61 7.92 -0.12 0.65 0.75
REL 206036_s_at 13 5.63 8.36 0.53 0.76 0.77
ABCC4 203196_at 22 5.84 7.54 0.09 0.78 0.89
FOXO1A 202724_s_at 19 5.91 7.43 -2.05 0.85 0.90
NOTCH2 212377_s_at 13 6.19 8.24 -0.43 0.77 0.82
TNFRSF21 214581_x_at 13 6.22 8.03 1.98 0.83 0.97
MADH9 206320_s_at 19 6.24 5.47 -2.29 0.87 0.74
PPM1D 204566_at 30 6.29 8.80 0.50 0.73 0.72
MAP7 202889_x_at 22 6.42 6.27 -3.51 0.85 0.87
DMBT1 208250_s_at 19 6.49 7.25 -6.49 0.20 -0.11
SNIP1 219409_at 13 6.57 8.34 1.08 0.69 0.77
OSF2 210809_s_at 19 6.59 7.68 -1.26 0.80 0.77
ATBF1 208033_s_at 19 6.64 7.14 0.27 0.81 0.84
KIT 205051_s_at 22 6.70 7.51 -2.73 0.86 0.87
P53 201746_at 19 7.00 8.50 -3.44 0.41 0.11
BAG3 217911_s_at 19 7.04 8.61 -0.98 0.79 0.82
RB 203132_at 19 7.04 9.14 -2.82 0.45 0.38
WBP4 203599_s_at 19 7.28 8.97 -0.24 0.62 0.74
BNIP2 209308_s_at 13 7.58 9.79 0.56 0.68 0.69
UMPCMPK 217870_s_at 13 8.17 10.98 1.10 0.37 0.12
DCAMKL1 205399_at 19 8.18 9.23 -3.57 0.76 0.89
OAZIN 201772_at 30 8.22 10.36 -0.36 0.72 0.77
LHFP 218656_s_at 19 8.37 9.27 -0.46 0.89 0.90
BTG3 205548_s_at 13 8.47 10.54 0.83 0.86 0.90
DCX 204850_s_at 19 8.81 10.08 0.62 0.87 0.88
TERF2 203611_at 19 9.05 10.04 -0.14 0.32 0.31
GADD45A 203725_at 19 9.17 9.80 -0.12 0.96 0.94
PRSS11 201185_at 19 9.22 9.85 -3.54 0.63 0.64
RAP1 201174_s_at 19 10.34 11.59 -0.82 0.83 0.84BMC Genomics 2005, 6:59 http://www.biomedcentral.com/1471-2164/6/59
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component of any microarray experiment, the genes
selected for validation a priori, are usually identified from
the microarray data. The selection is based on the implicit
assumption that there is a good correlation between the
microarray data and actual mRNA levels in the cells under
investigation. One fundamental issue that has not been
adequately addressed is how well microarray expression
scores reflect actual mRNA levels in the sample being
examined.
To facilitate data comparison between research groups it is
important that the microarray community moves to adopt
consistent validation methodologies. This is especially
important if microarray technology is to play a role in the
clinical setting [13]. However, the choice of validation
methodology remains a contentious issue [14]. To date,
qRT-PCR is the method of validation that has been used
in the majority of published microarray studies, presuma-
bly because it is a rapid, sensitive, high throughput proce-
dure that requires minimal amounts of test material
compared to techniques such as Northern blotting or
ribonuclease protection assays. As is the case for many
studies, including ours, qRT-PCR is often the only feasible
approach when rare or unique tissues are investigated. For
these reasons, it would appear likely that qRT-PCR will
continue to be used extensively for the validation of
microarray expression data [15]. To our knowledge, this
study is the most extensive and practical examination of
mammalian cells that focuses on the degree of correlation
between expression level measurements obtained by oli-
gonucleotide microarray analysis and qRT-PCR.
We observed strong correlations (p < 0.05) for the major-
ity (>87%) of the 31 transcript-concordant genes that we
examined in this study. In addition, although the MAS 5.0
software and RMA use different algorithms for the nor-
malization of microarray data [8,9] we found that the
degree of correlation between microarray and qRT-PCR
results was very similar irrespective of the normalization
procedure employed.
Our data clearly demonstrate that similar microarray
scores for different genes do not necessarily mean that
similar qRT-PCR scores will be obtained. For example,
ATBF1, OSF2, and SNIP1  yielded similar average log2
RMA scores (~6.6) but the average log2 qRT-PCR scores for
the same genes were substantially different (0.27, -1.26,
and 1.08, respectively). Similarly, KIT and ABCC4 exhib-
ited identical average log2 MAS 5.0 scores (~7.5), while
the corresponding average log2 qRT-PCR scores were -2.73
and 0.09, respectively. The finding that genes with similar
microarray expression scores were unlikely to have similar
qRT-PCR results presumably reflects the different hybridi-
zation kinetics of the probe sets for each gene. This
Table 2: A comparison of average qRT-PCR, RMA, and MAS 5.0 scores and the corresponding correlation values for the 17 genes 
assayed in this study for which the Affymetrix microarray probesets (Affy IDs) may not recognize the exact same transcript subsets 
recognized by qRT-PCR probes. Genes are ranked from lowest to highest average log2 RMA scores. Genes with significant correlations 
(p < 0.05) obtained by either normalization procedure are highlighted in bold. The number of specimens tested for each gene is 
included (n). Expression levels are shown as log2.
GENE EXPRESSION CORRELATION




CDC14A 210742_at 13 5.77 7.64 -0.67 0.31 0.26
P125 209175_at 19 6.61 8.43 0.54 0.11 -0.11
GCLC 202922_at 13 6.65 9.20 0.33 0.46 0.56
MAP3K7 206853_s_at 13 6.65 8.72 1.19 0.11 -0.10
TIAL1 202405_at 19 6.68 7.86 0.30 0.32 0.17
FLJ20003 219067_s_at 19 6.71 8.54 0.64 0.64 0.34
RUNX1 210365_at 13 6.95 9.24 1.47 0.29 0.28
PLEKHA1 219024_at 19 6.99 8.18 -2.88 -0.40 -0.28
FLJ12661 218420_s_at 19 7.35 8.50 0.57 -0.08 -0.17
RGC32 218723_s_at 19 7.36 8.11 -3.20 0.85 0.96
WDR11 218090_s_at 19 7.96 9.04 0.60 0.12 0.01
RFC3 204127_at 19 8.10 9.77 1.20 0.62 0.64
ASAH1 213702_x_at 22 8.30 10.29 1.46 0.29 0.27
P38IP 220408_x_at 19 8.35 9.55 0.76 0.73 0.65
BUB3 201456_s_at 19 8.41 9.70 0.60 0.64 0.61
SAC2 203607_at 19 8.86 10.21 0.35 0.22 0.12
TSC22 215111_s_at 19 10.56 11.87 -1.34 0.83 0.82BMC Genomics 2005, 6:59 http://www.biomedcentral.com/1471-2164/6/59
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Examples of Pearson's correlations between gene expression levels determined by qRT-PCR and oligonucleotide microarray  for one gene assessed in this study Figure 1
Examples of Pearson's correlations between gene expression levels determined by qRT-PCR and oligonucleotide microarray 
for one gene assessed in this study. The mRNA levels for the gene GADD45A were determined by qRT-PCR and correlated 
with microarray expression scores determined after data processing using MAS 5.0 software (A) or RMA (B). All data are 
shown as log2.
A
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Pearson's correlations between fold-change in average gene expression levels between subsets of interest assessed by qRT- PCR and either MAS 5.0 software (A) or RMA (B) for the 31 transcript-concordant genes (see Table 1) Figure 2
Pearson's correlations between fold-change in average gene expression levels between subsets of interest assessed by qRT-
PCR and either MAS 5.0 software (A) or RMA (B) for the 31 transcript-concordant genes (see Table 1). All data are shown as 
log2.
A
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observation has the major implication that on the basis of
the qRT-PCR data that we obtained, it is generally not fea-
sible to predict the true expression level of one gene based
on the microarray expression score of another. In addi-
tion, we observed significant correlations for many genes
with microarray expression scores, at least by RMA, of less
than 100 (~log2100 = 6.64), which is at the lower end of
the range of microarray scores we obtained in this study
(range 6–23000). This finding indicates that the exclusion
of genes with low microarray expression scores (e.g. <100)
from further analysis, as has been adopted by some
research groups in early microarray studies, may not be
justified.
Determining fold-changes in gene expression levels
between subsets of interest is often a critical aim of micro-
array studies. We found a significant and strong correla-
tion using RMA (r = 0.89, p < 0.05) and MAS 5.0 (r = 0.92,
p < 0.05). These data indicate that the direction of change
of gene expression levels (i.e. either up or down regula-
tion) between subsets of interest is accurately predicted by
comparison of average microarray expression scores.
Again, the fold-change correlations we observed were very
similar irrespective of the normalization procedure we
employed. Consistent with the results of Yuen et al
(2001)[16], fold change results determined by qRT-PCR
were significantly greater than fold change assessed for the
same genes by microarray analysis.
A recent study addressing gene expression profiles in Ara-
bidopsis reported a good correlation between oligonucle-
otide microarray and SYBR green qRT-PCR data when
ratios of gene expression in shoot tissue versus root tissue
were compared for highly expressed genes. However, the
correlations between shoot versus root ratios were gener-
ally poor for genes expressed at low levels [17]. We
observed a similar trend towards poorer correlation for
genes that exhibited fold-change differences of <1.5
between subsets of interest based on microarray expres-
sion scores compared to those with fold-change differ-
ences of >1.5. It is likely that this trend relates to the fact
that small variations in mRNA levels (<2-fold) can be
accurately detected by qRT-PCR, while the smaller
dynamic range of microarrays means that the same
changes may not be accurately reflected by microarray
expression scores, especially for genes expressed at low
levels (<1.5 pM or approximately 3.5 copies/cell) [18,19].
This latter point is a likely explanation for the poor corre-
lation observed for one gene, DMBT1, which is expressed
at very low levels according to our qRT-PCR data. Etienne
et al., 2004 [20] observed a lower overall correlation
between microarrray and semi-quantitative RT-PCR data
compared to our study. These authors hypothesized that
in addition to genes with low expression levels, those with
very high expression levels or a greater percentage of
absent calls, may show lower levels of correlation between
Affymetrix expression scores and semi-quantitative RT-
PCR data. We considered these issues in relation to the
other poorly correlating genes in our study and found that
none were expressed at levels that approach the fluores-
cence ceiling for the Affymetrix scanner (~50000). In
addition, the absolute number or percentage of absent
calls did not correlate significantly (p > 0.05) with the
level of correlation between qRT-PCR results and microar-
ray data (data not shown). It is possible that the differ-
ences between our results and those of Etienne and co-
workers are related to the particular semi-quantitative RT-
PCR methodology employed by these researchers, which
may not be as sensitive as qRT-PCR, and as the authors
point out, may not detect certain low level transcripts.
In addition to DMBT1 mentioned above, we identified 13
other poorly correlating genes from the 48 genes we
assessed. Careful analysis of the alternative transcript data
available through the LocusLink database http://
www.ncbi.nih.nlm/LocusLink indicated that for 10 of
these 13 genes, different subsets of alternative transcripts
may be recognized by microarray probe sets and qRT-PCR
probes. Hence, this may be the explanation for the poor
correlations observed for these genes. Possible explana-
tions for the poor correlations that were observed for the
three remaining genes (p53, UMPCMPK, and TERF2), all
of which were transcript-concordant, include the exist-
ence of alternative cross-hybridising transcripts differen-
tially recognized by the oligonucleotide probe sets and
qRT-PCR probes, gene specific variation related to the dif-
ferent hybridization kinetics associated with the two tech-
nologies, and misleading results associated with errors in
GenBank sequence data and/or probe set annotations
[21]. Additional experimental data will be required to
address these possibilities. It is important to note that in
our hands the reproducibility of both the qRT-PCR and
oligonucleotide microarray methods is very high [22,23].
Hence, it is unlikely that poor correlations observed in our
study are associated with issues of experimental precision.
Interestingly, the microarray and qRT-PCR expression
data correlated well for five genes for which the microar-
ray probe sets were deemed unlikely to recognize the same
transcripts as the qRT-PCR probes. These data suggest that
despite the possibility of differential transcript recogni-
tion, identical transcripts were being detected by both
assays in the particular tissues involved.
Conclusion
Our data indicate that correlations between qRT-PCR and
microarray data are generally strong; a result that is partic-
ularly encouraging for those researchers with access to
only very limited amounts of rare or unique test speci-
mens. Our data also emphasize the importance of ensur-BMC Genomics 2005, 6:59 http://www.biomedcentral.com/1471-2164/6/59
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ing that qRT-PCR probes recognize the same transcript(s)
as the microarray probe set. Finally, the 13–16% non-con-
cordance that we observed indicates that independent val-




Informed consent for the use of tissues for research pur-
poses was obtained for all individuals involved in this
study according to hospital and Australian National
Health and Medical Research (NHMRC) guidelines.
We extracted total RNA from 64 specimens, including 13
primary pediatric brain tumors, six pediatric brain tumor
cell lines, two normal adult brain cortices, and one fetal
brain germinal matrix. We also obtained total RNA from
fetal brain pooled from multiple individuals (Clontech).
In addition, total RNA was extracted from 36 pediatric
acute lymphoblastic leukemia bone marrow specimens
and from CD34+ hematopoietic stem cells isolated from
the bone marrows of 5 normal individuals. Ficoll-
hypaque purified leukemia cells or cryopreserved bone
marrow specimens were snap frozen and stored in liquid
nitrogen until required. Total RNA was extracted from ~1
× 106 – 2 × 107 live cells. Primary brain tumour specimens
(10 – 150 mg) were either wrapped in foil or placed in
RNAlater (Ambion) immediately after resection and
stored at -80°C. Brain tumour cell lines were processed
directly from tissue culture.
RNA extraction, preparation of target cRNA and 
hybridization to HG-U133A GeneChips
Total RNA was extracted from all specimens using a com-
bination of TRIZOL reagent (Invitrogen), RNeasy Mini kit
(Qiagen) and ethanol precipitation. Following the TRI-
ZOL reagent procedure, 0.53 volumes of 100% ethanol
were added drop-wise to the aqueous phase and the mix-
ture applied to RNeasy mini columns according to the
manufacturer's instructions. Further purification and con-
centration was achieved through an additional ethanol
precipitation. The integrity of the RNA preparation was
assessed using agarose gel electrophoresis and analysis on
an Agilent 2100 Bioanalyzer (Agilent Technologies).
Biotinylated cRNAs for hybridization were prepared from
total RNA according to Affymetrix protocols. Agarose gel
electrophoresis was used to confirm the integrity of
labelled cRNA and to assess its fragmentation products.
Biotinylated cRNA preparations (15 µg) were hybridized
to HG-U133A arrays, which were subsequently washed,
stained, and scanned using a GeneArray Scanner (Agilent
Technologies) according to the Affymetrix protocol.
Processing and statistical analysis of microarray data
Array images were reduced to intensity values for each
probe (cel files) using Affymetrix MAS 5.0 software and
only those microarrays meeting acceptable Affymetrix
quality control criteria were considered for further
analysis. Cel files were then processed using either the
MAS 5.0 software [8] or RMA (Bioconductor release 1.2)
[9], an alternative algorithm that is publicly available at
http://www.bioconductor.org. The MAS 5.0 algorithm
uses a scalar normalization technique taking into account
perfect match (PM) and mismatch (MM) probe pairs to
correct for non-specific hybridization, while RMA is based
on a quantile normalization approach which ignores MM
values. All microarrays processed using the MAS 5.0 soft-
ware were scaled to a standard target intensity of 500. For
comparison purposes, all microarray and qRT-PCR data
are presented as log2 and absent/present calls generated by
the MAS 5.0 software were not taken into account.
Pearson's correlations were used for the comparison of
qRT-PCR and microarray data and p-values were obtained
using Fisher's z-transformation. Correlations were consid-
ered significant at p < 0.05.
Bioinformatics
To determine whether transcripts recognized by microar-
ray probe sets [24] were likely to be identical to those
detected by qRT-PCR probes, alternative splicing patterns
for each gene were thoroughly reviewed using LocusLink
http://www.ncbi.nlm.nih.gov and Ensembl http://
www.ensembl.org. Any full-length human mRNA or
cDNA sequences demonstrating alternative splicing, in
addition to NCBI-reviewed Reference Sequences (RefSeq),
were considered as potential isoforms for each gene.
Using BLAST alignments http://www.ncbi.nlm.nih.gov of
probe and cDNA sequences, the members of each isoform
'family' that could be targeted by either qRT-PCR or
microarray were identified (typically multiple isoforms
for each gene). The potential number of isoforms recog-
nised by each technology were then compared. Probes
which targeted exactly the same isoform subsets for each
gene were considered 'transcript-concordant' and placed
in Table 1; those for which at least one of the targeted iso-
forms differed (regardless of the number of matching iso-
forms) were considered 'non transcript-concordant' and
placed into Table 2.
qRT-PCR
All qRT-PCR assays were carried out using primer and
probe sets from Applied Biosystems (ABI Assays on
Demand, http://www.appliedbiosystems.com/). Each
assay was designed using ABI's primer/probe selection
algorithm and bionformatics pipeline which includes
access to both public and Celera DNA sequence databases.BMC Genomics 2005, 6:59 http://www.biomedcentral.com/1471-2164/6/59
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The combination of gene specific primers and a gene spe-
cific probe ensures a high degree of specificity.
Aliquots of total RNA extracted for microarray analysis as
described above were used for qRT-PCR experiments
according to the manufacturer's protocols (ABI). All ABI
Assays on Demand are designed to generate amplicons of
50–150 bp and are carried out using identical cycling con-
ditions. 1–2 ug total RNA (quantitated by spectrophotom-
eter at OD260) was used for each RT reaction. Three RT
reactions were pooled and all qRT-PCR reactions were car-
ried out using aliquots from the pool. We did not detect
DNA contamination in any of our total RNA preparations
after qualitative assessment using an Agilent Bioanalyzer.
All qRT-PCR assays for a particular gene were undertaken
at the same time under identical conditions and carried
out in duplicate. All qRT-PCR experiments were run on an
ABI 7700 sequence detector.
For all qRT-PCR assays the expression levels of target
genes were normalised to the levels of the ACTB house-
keeping gene utilising a standard curve method for quan-
titation as described previously [25]. Serial dilutions of
cDNAs generated from selected cell lines that expressed
target genes at a suitable level were used to generate a
standard curve for each target gene and ACTB. The stand-
ard curves were then used to determine expression values
(expressed as ng cDNA template) for each target gene after
qRT-PCR analysis of each test specimen. Relative expres-
sion values for each target gene were expressed as a ratio
of target gene expression level to ACTB expression level in
the same specimen. These ratios were then correlated with
the microarray data.
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